Descripción de la empresa
Zhengye Biotechnology Holding Limited operates within the healthcare sector, specifically focusing on the drug manufacturing industry for specialty and generic pharmaceuticals, primarily targeting the veterinary market. The company is dedicated to the research, development, manufacture, and sale of veterinary vaccines for livestock in China, offering a comprehensive portfolio that includes vaccines for swine, cattle, goats, sheep, poultry, and dogs. Its product line encompasses monovalent, polyvalent, and combined vaccines designed to address specific disease challenges across various animal species. The firm employs a workforce of 277 individuals and maintains a market capitalization of $43.46M with reported annual revenue of $153.74M. These valuation and revenue figures indicate that the company functions as a small-cap entity with a specialized niche position in the Chinese veterinary pharmaceutical landscape, reflecting a scale that supports regional operations but limits broad diversification compared to large-cap peers.
Salud financiera
The company reported revenue of $153.74M over the trailing twelve months, accompanied by a net income of -$19,368,000 and an EBITDA of -$2,213,000. The significant gap between the $153.74M in revenue and the negative net income reveals a cost structure where operating expenses, likely driven by research and development or manufacturing overhead, substantially exceed gross profits. Despite the accounting losses, the company generated free cash flow of $24.23M, which indicates a degree of financial flexibility allowing for operational continuity without immediate reliance on external equity financing. Analysis of the three primary margins shows a gross margin of 37.4%, an operating margin of -46.3%, and a profit margin of -12.6%. The robust gross margin suggests efficient production relative to sales, whereas the deeply negative operating margin highlights high fixed costs or administrative expenses that are not yet covered by core operations. On the balance sheet, the firm holds $47.63M in cash against total debt of $85.76M, resulting in a debt-to-equity ratio of 23.49, which characterizes a leveraged financial position rather than a conservative one. The current ratio stands at 1.49, indicating that the company possesses sufficient current assets to cover its short-term liabilities with a moderate buffer. Additionally, the return on equity is -6.4% and the return on assets is -3.4%, metrics that reveal that management has not yet generated positive returns on the capital invested or assets utilized, signaling a period of investment or restructuring.
Evaluación de valoración
The trailing P/E ratio is N/A and the forward P/E is also N/A, implying that earnings-based valuation multiples are currently inapplicable due to the company's consistent net losses and lack of expected earnings turnaround in the immediate future. The price-to-book ratio is 1.00, which indicates that the market values the company's equity at par with its book value, suggesting no significant premium or discount relative to the tangible assets recorded on the balance sheet. Alternative valuation metrics provide further context, with a price-to-sales ratio of 0.28 and an EV/EBITDA of -66.77; these figures suggest the market is pricing the stock based on revenue generation and asset value rather than profitability or cash earnings power. The 52-week high is $14.30 and the 52-week low is $0.68, providing a trading range of $13.62. Without a specific current price provided in the facts to calculate the exact percentage, the stock's position within this range defines its recent volatility and investor sentiment extremes. The beta value is N/A, meaning that data regarding the stock's price volatility relative to the broader market is not available for this reporting period.
Growth & Income
The revenue growth year-over-year is -34.4% and the earnings growth year-over-year is N/A, indicating a contraction in sales volume or pricing power that has directly impacted profitability. Because earnings growth is not calculable due to losses, it is impossible to determine if earnings are growing faster or slower than revenue, though the negative revenue growth implies a challenging operating environment. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the firm reinvests all available cash flow and retained earnings back into operations, research, or debt reduction rather than distributing income to shareholders. This non-dividend profile is typical for biotechnology and specialty pharmaceutical companies that prioritize capital allocation toward growth initiatives over current income distribution. The overall growth and income profile is characterized by declining revenue, negative returns, and a lack of dividend support, reflecting a company in a turnaround or heavy investment phase within the veterinary vaccine sector.